BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
Morgan Healthcare Conference to outline strategic priorities for 2026, provide preliminary 2025 revenue figures, and highlight a slate of upcoming regulatory and clinical catalysts. Chief Executive Officer Alexander Hardy said the company has been “transforming BioMarin” over the past 24 months and is targeting an additional period of growth driven by Voxzogo, its enzyme therapies portfolio, and the pending acquisition of Amicus. Hardy framed BioMarin's strategy around three pillars introduced at the company's September 2024 Investor Day: innovation, growth, and a “value commitment” focused on operating leverage. He said BioMarin has prioritized pipeline programs it views as having the most transformative potential and pointed to accelerated progress for two pipeline assets, BMN 333 and BMN 351. ? NVIDIA's Next Leg Higher May Have Started at CES 3 Oversold Stocks with Big RSI Rebound Potential For 2026, Hardy said BioMarin's priorities are to: Accelerate revenue by expanding
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC]CNBC
- Does BioMarin Pharmaceutical (BMRN) Price Weakness Contrast With Its Cash Flow Valuation? [Yahoo! Finance]Yahoo! Finance
- BMRN or TARS: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer [Yahoo! Finance]Yahoo! Finance
- BioMarin Appoints Arpit Davé Chief Digital and Information OfficerPR Newswire
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 1/12/26 - Form 8-K
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- BMRN's page on the SEC website